株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

デジタル活動動向:乳がん

Digital Landscape: Breast Cancer

発行 GlobalData 商品コード 703431
出版日 ページ情報 英文 155 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.05円で換算しております。
Back to Top
デジタル活動動向:乳がん Digital Landscape: Breast Cancer
出版日: 2018年09月12日 ページ情報: 英文 155 Pages
担当者のコメント
乳がんにおけるデジタルマーケティング市場をまとめたレポートです。米国と欧州各国の普及国にフォーカスして動向をまとめております。
概要

当レポートでは、世界の主要国 (米国、およびEUCAN加盟国 (カナダ、英国、ドイツ、フランス、イタリア、スペイン)) にて、製薬企業が乳がん治療薬の開発活動促進・啓発活動支援のために取り組んでいる各種のデジタル活動 - ブランド薬Webサイト、非ブランド薬の啓発活動、ソーシャルメディア/モバイルアプリなど - について分析しております。

目次

  • エグゼクティブ・サマリー
  • 近年の動向
  • 市場環境・分析
    • 米国:患者向け活動
    • 米国:HCP (医療機関) 向け活動
    • EUCAN:患者向け活動
    • EUCAN:HCP向け活動
  • 分析手法

分析対象企業:Pfizer、Novartis、AstraZeneca、Roche/Genentech、Eli Lilly、エーザイ、Puma Technology、Celgene、R-Pharma、MidatechPharma、協和発酵キリン、TerSera Therapeutics、Amgen

目次
Product Code: GDHC044SP

"Digital Landscape: Breast Cancer", analyzes digital activities undertaken by pharma in support of therapies for Breast Cancer.

  • The report includes digital activities directed towards patients and/or HCPs
  • The geographic scope of the report is the United States, EUCAN(Canada and the 5EU countries: UK, Germany, France, Italy & Spain).
  • The main focus of the report is hormonal and targeted therapies, and certain branded chemotherapy drugs.

Key Highlights

  • US Patients: Strong digital support for US breast cancer patients in the US, particularly from Pfizer, Novartis and AstraZeneca. Most recent branded activity seen from Lilly and Novartis in the CDK4/6 inhibitor space. Most unbranded and social media activity focuses on supporting patients with metastatic breast cancer. Few breast cancer-specific mobile apps detected in the US.
  • US HCPs: There is little support for HCPs in the breast cancer space beyond branded. AstraZeneca, Genentech, Novartis and Pfizer offer examples of strong branded resources. The pharma-sponsored unbranded and mobile app landscapes are sparse. Opportunities may exist to develop or sponsor content with trusted non-pharma organizations. HCP-directed social media activity restricted to posts from corporate accounts.
  • EUCAN Patients: Good support for EUCAN breast cancer patients from pharma, particularly those in France. Support is weakest in the UK and Spain. Strong unbranded support but no multi-country, local-language campaigns seen. Majority of unbranded sites supported by social media. Good examples of pharma-sponsored mobile apps. Features include disease tracking and reminders, as well as emotional support.
  • EUCAN HCPs: Limited pharma-sponsored support for EUCAN HCPs in breast cancer, with most activity seen in Germany. The unbranded and mobile app landscapes are undeveloped, and like the US, partnerships with non-pharma organizations may offer more effective opportunities to engage with and support HCPs.

Companies Mentioned: Pfizer, Novartis, AstraZeneca, Roche / Genentech, Eli Lilly, Eisai, Puma Technology, Celgene, R-Pharma, MidatechPharma, Kwoya Kirin, TerSera Therapeutics, Amgen.

Scope

  • This report analyzes digital activities undertaken by pharma in support of therapies for breast cancer.
  • The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps.
  • The report is based on analysis conducted by a combination of GlobalData's digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction.
  • The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout.
  • This report covers the research period from January 2017 - March 2018.

Reasons to buy

  • Our Digital Landscape report provides an analysis of pharma multichannel activity in the digital breast cancer space, and can assist our pharma clients derive value in a number of ways.
  • Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in breast cancer
  • Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns
  • Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands
  • Business Development & Licensing: Assess topics and trends shaping digital health in breast cancer and beyond, and learn about key patient and physician online activities in breast cancer.

Table of Contents

  • Executive Summary
  • Recent Developments
  • Landscape & Analysis
  • >US: Patient-directed Activities
  • >US HCP-directed Activities
  • >EUCAN Patient-directed Activities
  • >EUCAN HCP-directed Activities
  • Methodology
Back to Top